BioLineRx Ltd.
BLRXHealthcareNASDAQBiotechnology · Last scanned Oct 23, 2026
Scan Results
Daily timeframeBioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company carries a $10.3M market cap, placing it firmly in the micro-cap category. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Market Cap
$10.3M
Beta
0.70
P/E (TTM)
—
P/E (Fwd)
-0.82
EPS (TTM)
$0.00
EPS (Fwd)
$-2.52
ROE
-55.3%
ROA
-19.8%
Cash
$13.1M
Total Debt
$7.9M
Free CF
-$8.9M
52W Change
-43.7%
Annual Financials
Cash vs Debt
Where BLRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BLRX finished 27.74% below its 150-day moving average ($2.74) and 28.78% below its 200-day moving average ($2.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLRX overbought or oversold?
At the October 20, 2026 close, BLRX's RSI(14) was 6.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $13.1M in cash comfortably exceeding the $7.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$8.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -55.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioLineRx Ltd. and its sector.